cbdMD, Inc. Announces Closing of $2.25 Million Series C Preferred Stock Private Placement

PR Newswire

CHARLOTTE, N.C., Dec. 19, 2025 /PRNewswire/ — cbdMD, Inc. (NYSE American: YCBD), a leading wellness company and the parent of Herbal Oasis THC seltzers, ATRx functional mushroom supplements, and Paw CBD, today announces that it has entered into securities purchase agreements with institutional investors whereby Company issued the investors an aggregate of 1,000,000 shares of Series C Convertible Preferred Stock in consideration of gross proceeds to the Company of $2.25 million. The Company intends to use the net proceeds of approximately $2.1 million for working capital general corporate purposes and support ongoing strategic initiatives. The Series C shares have a 10% annual dividend and are convertible at the option of the holder into the Company’s common stock at an initial conversion price of $2.25 per share, subject to certain anti-dilution protection provisions, with rights and preferences substantially the same as the Company’s issued and outstanding Series B Convertible Preferred Stock.

“We are pleased to continue strengthening our balance sheet to assist the Company’s ongoing initiatives to expand distribution for its consumer brands, and position cbdMD for sustained profitability,” said Ronan Kennedy, Chief Executive Officer and Chief Financial Officer of cbdMD.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD) is a leading wellness company offering a comprehensive line of U.S.-produced, hemp-derived cannabinoid products, including CBD, CBG, CBN, and more. Its brands include:

  • Herbal Oasis – a hemp-derived THC social seltzer redefining the way people connect, unwind, and celebrate life.
  • ATRx Labs – functional mushroom supplements supporting focus, calm, and vitality.
  • Paw CBD – one of the most recognized CBD brands for pets.

The Company is committed to quality, innovation, and transparency, with products distributed both online and through retail partners across the United States. To learn more about cbdMD and our comprehensive line of U.S. grown hemp products as well as our other brands, please visit www.cbdmd.com, www.herbaloasis.com, www.pawcbd.com, or ATRxlabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD’s products.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding profitability and maintaining listing requirements. Such forward-looking statements can be identified using words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as filed with the Securities and Exchange Commission (the “SEC”) on December 17, 2024, and our other filings with the SEC. All forward-looking statements, including, involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

Contact Information:

cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
[email protected]
(704) 445-3064

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cbdmd-inc-announces-closing-of-2-25-million-series-c-preferred-stock-private-placement-302647242.html

SOURCE cbdMD, Inc.

American Drive Acquisition Company Announces Closing of $230 Million Initial Public Offering

PR Newswire

WASHINGTON, Dec. 19, 2025 /PRNewswire/ — American Drive Acquisition Company (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced the closing of its initial public offering of 23,000,000 units at a price of $10.00 per unit on December 19, 2025, which includes the exercise in full by the underwriters of their overallotment option to purchase an additional 3,000,000 units. Total gross proceeds from the offering were $230 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

The units began trading on The Nasdaq Global Market (“Nasdaq”) under the ticker symbol “ADACU” on December 18, 2025. Each unit consists of one Class A ordinary share of the Company and one-third of one redeemable public warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq under the symbols “ADAC” and “ADACW,” respectively.

Cantor Fitzgerald & Co. acted as sole book-running manager for the offering.

The public offering was made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, New York, NY 10022, Attention: General Counsel, or by email at: [email protected].

A registration statement relating to the securities became effective on December 17, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the anticipated use of the net proceeds from the offering. No assurance can be given that the net proceeds of the offering will be used as indicated, or that the Company will ultimately complete a business combination transaction. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the Company’s offering filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Cision View original content:https://www.prnewswire.com/news-releases/american-drive-acquisition-company-announces-closing-of-230-million-initial-public-offering-302647228.html

SOURCE American Drive Acquisition Company

Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Enlicitide has potential to be first approved oral PCSK9 inhibitor designed to help meet critical unmet needs for patients and will be offered at an affordable price to eligible Americans through a direct-to-patient program

Merck has committed more than $70 billion in U.S. investments to boost domestic production and innovation

RAHWAY, N.J.–(BUSINESS WIRE)–
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a historic agreement with the Trump administration to ensure its prescription medicines are both accessible and affordable for Americans. This agreement enables Merck to continue its long-standing commitment to develop and deliver life-changing medicines and vaccines, and ensure Americans have access to those innovations at lower costs.

“As an American company, Merck is proud to work with the Trump administration to further secure our country’s position as a world leader in biopharmaceutical innovation. Today’s agreement marks a pivotal step in ensuring Americans can access medicines they need at lower costs,” saidRobert M. Davis, chairman and chief executive officer, Merck. “For too long, global pricing imbalances have shifted the financial burden of groundbreaking research and development onto the U.S. health care system and ultimately, American patients. Merck remains committed to expanding access and improving affordability across the system.”

Merck is working with the administration to reduce disparities in drug prices between the U.S. and other nations so American patients no longer shoulder a disproportionate share of the cost of innovation. Merck is voluntarily addressing all four components of the president’s July letter and taking steps that will help ensure Americans can benefit from lower prices and broader access to prescription medicines.

Information on Merck’s agreement with the Trump administration

Merck plans to provide key products through a direct-to-patient program at affordable prices for eligible patients in the U.S. This currently includes JANUVIA, JANUMET and JANUMET XR, and will be expanded in the future to include enlicitide decanoate following FDA approval.

JANUVIA, JANUMET and JANUMET XR will be available to eligible American patients at a cash price — approximately 70% off of the current list price — through a direct-to-patient program.

Enlicitide, a novel candidate to lower LDL cholesterol, was designed to deliver PCSK9 antibody-like efficacy in an easy-to-use daily pill. Although existing injectable PCSK9 inhibitors are effective, they remain widely underused. The cardiovascular (CV) epidemic is the leading cause of deaths in America with heart attacks and stroke contributing to most of the CV deaths — one person dies every 36 seconds from cardiovascular disease. If approved, we intend to make enlicitide broadly available as an affordable option for American patients to help address the CV epidemic.

Additionally, the company reached an understanding with the U.S. Department of Commerce to delay Section 232 tariffs for three years, enabling the company to make investments in the United States to reshore manufacturing for American patients.

Merck investments in American innovation

Merck has accelerated its commitment to U.S. innovation and manufacturing, building on its 15 manufacturing and R&D facilities and a strong workforce in the U.S. of more than 30,000. The company has invested over $12 billion in U.S. manufacturing since 2017 and $81 billion in U.S.-based R&D since 2018, supporting tens of thousands of American jobs. Over the next several years, Merck will invest more than $70 billion in capital and R&D spending, including at least $12 billion in capital expenditures, to drive long-term growth and strengthen the U.S. position as a global leader in biopharmaceutical innovation. This includes Merck’s recent announcements of manufacturing facilities in Virginia, Kansas and Delaware, which alone will create 1,200 full-time jobs and support 15,000 construction jobs.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world — and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Appendix

Generic product names are provided below.

  • JANUMET (sitagliptin and metformin HCl)
  • JANUMET XR (sitagliptin and metformin HCI extended-release)
  • JANUVIA (sitagliptin)

Media Contacts:

John Cummins

[email protected]

Melissa Moody

[email protected]

Investor Contacts:

Peter Dannenbaum

(732) 594-1579

Steven Graziano

(732) 594-1583

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Public Policy/Government Clinical Trials Healthcare Reform Biotechnology Other Health Managed Care Health Pharmaceutical Oncology

MEDIA:

Logo
Logo

Bitmine Invites Stockholders to Attend its Annual Meeting Held in Las Vegas on January 15, 2026; Encourages Stockholders to Cast Their Votes

PR Newswire

Stockholders have been notified of the Annual Meeting through mail, telephone/text, and email communications

Bitmine leads crypto treasury peers by both the velocity of raising crypto NAV per share and by the high trading liquidity of BMNR stock

Bitmine remains supported by a premier group of institutional investors including ARK’s Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas “Tom” Lee to support Bitmine’s goal of acquiring 5% of ETH

LAS VEGAS, Dec. 19, 2025 /PRNewswire/ — (NYSE AMERICAN: BMNR) Bitmine Immersion Technologies (“Bitmine” or the “Company”) a Bitcoin and Ethereum Network Company with a focus on the accumulation of crypto for long term investment, encourages shareholders to vote and attend its in-person Annual Meeting for Stockholders (“Annual Meeting”) held at the Wynn Las Vegas on January 15, 2026. Details and the agenda for this year’s Annual Meeting can be found below:

Bitmine’s Annual Meeting:

  • Location: Wynn Las Vegas, 3131 Las Vegas Blvd S, Las Vegas, Nevada 89109
  • Timing: 12:00pm-3:00pm PST
  • Agenda:

1. Elect eight (8) directors for the next year;
2. Approve the charter amendment to increase the number of authorized shares of common stock;
3. Approve the 2025 Omnibus Incentive Plan; and
4. Approve, on a non-binding advisory basis, the special, performance-based compensation arrangement for the executive chairman

  • Attending the Annual Meeting: Stockholders wishing to attend the Annual Meeting in person must register in advance at https://web.viewproxy.com/BMNR/2026 and follow the instructions provided. Registration must be completed and submitted no later than January 13, 2026 at 11:59 p.m. Eastern Time.

    • On the day of the meeting, please be ready to show your ticket and photo ID at the door for entry. If you have any questions, or need assistance with the registration process please contact Alliance Advisors at [email protected].
  • Voting: Stockholders can vote either in person at the Annual Meeting or by proxy whether or not you attend the Annual Meeting utilizing one of the following methods:

    • By mail: All stockholders of record who received paper copies of the company’s proxy materials can vote by marking, signing, dating, and returning their proxy card.
    • By telephone: Please call the number listed on your proxy card and follow the recorded instructions. You will need the control number included on your proxy card.
    • By internet: Please visit https://AALvote.com/BMNR or, if you received printed copies of your proxy materials, scan the QR code located on your proxy card. You will need the control number included on your proxy card.
    • The telephone and internet voting facilities for the stockholders of record of all shares will close at 11:59 p.m., Eastern Time on January 14, 2026.
  • If you have any questions or need assistance please contact Alliance Advisors at
    • 1-855-206-1722 or [email protected]
    • Hours of Operation:
      • Monday – Friday: 9am-10pm EST
      • Saturday – Sunday: 10am – 10pm EST

The annual meeting will be livestreamed on Bitmine’s X account: https://x.com/bitmnr 

The Chairman’s message can be found here:
https://www.bitminetech.io/chairmans-message 

The Fiscal Full Year 2025 Earnings presentation and corporate presentation can be found here: https://bitminetech.io/investor-relations/  

To stay informed, please sign up at: https://bitminetech.io/contact-us/  

About Bitmine
Bitmine is a Bitcoin and Ethereum Network Company with a focus on the accumulation of Crypto for long term investment, whether acquired by our Bitcoin mining operations or from the proceeds of capital raising transactions. Company business lines include Bitcoin Mining, synthetic Bitcoin mining through involvement in Bitcoin mining, hashrate as a financial product, offering advisory and mining services to companies interested in earning Bitcoin denominated revenues, and general Bitcoin advisory to public companies. Bitmine’s operations are located in low-cost energy regions in Trinidad; Pecos, Texas; and Silverton, Texas.

For additional details, follow on X:
https://x.com/fundstrat
https://x.com/bmnrintern

Forward Looking Statements
This press release contains statements that constitute “forward-looking statements.” The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. This document specifically contains forward-looking statements regarding progress and achievement of the Company’s goals regarding ETH acquisition and staking, the long-term value of Ethereum, continued growth and advancement of the Company’s Ethereum treasury strategy and the applicable benefits to the Company. In evaluating these forward-looking statements, you should consider various factors, including Bitmine’s ability to keep pace with new technology and changing market needs; Bitmine’s ability to finance its current business, Ethereum treasury operations and proposed future business; the competitive environment of Bitmine’s business; and the future value of Bitcoin and Ethereum. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond Bitmine’s control, including those set forth in the Risk Factors section of Bitmine’s Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2025, as well as all other SEC filings, as amended or updated from time to time. Copies of Bitmine’s filings with the SEC are available on the SEC’s website at www.sec.gov. Bitmine undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bitmine-invites-stockholders-to-attend-its-annual-meeting-held-in-las-vegas-on-january-15-2026-encourages-stockholders-to-cast-their-votes-302647223.html

SOURCE BitMine Immersion Technologies, Inc.

Settlement Reached in Multiple PUCO FirstEnergy Proceedings

PR Newswire

Settlement provides $275 million to FirstEnergy Ohio customers 

AKRON, Ohio, Dec. 19, 2025 /PRNewswire/ — FirstEnergy Corp.’s Ohio electric companies – Ohio Edison, Toledo Edison and The Illuminating Company – have reached an agreement with parties to settle multiple Public Utilities Commission of Ohio (PUCO) matters and provide $275 million to FirstEnergy’s Ohio customers.

The settlement resolves four PUCO proceedings – the Corporate Separation, Rider DMR and Rider DCR matters that were the subjects of the PUCO’s Nov. 19 orders and the pending Political and Charitable Spending review. The PUCO’s Nov. 19 orders directed the companies to pay $250 million, with $64 million going to the state general fund. If approved by the PUCO, the settlement will direct all $250 million to all customers and add $25 million exclusively for residential customers.

Torrence Hinton, FirstEnergy President, Ohio: “We appreciate the dedication and collaboration shown by all parties and are grateful for the collective effort that led to an agreement that provides even more dollars to our Ohio customers. With these matters reaching resolution, we’re moving ahead with a clear focus on operating with transparency, delivering reliable service and investing in Ohio communities.”

Key Settlement Details 
Settlement provisions include:

  • $250 million in restitution and refunds, credited to customer bills in 2026
  • $25 million in additional restitution exclusively to residential customers, including $20 million for low-income bill payment assistance, weatherization and energy efficiency programs

Parties to the settlement include The Office of the Ohio Consumers’ Counsel (OCC), Ohio Manufacturers’ Association Energy Group (OMAEG), Ohio Energy Group (OEG), Northeast Ohio Public Energy Council (NOPEC), Northwest Ohio Aggregation Coalition (NOAC), Ohio Partners for Affordable Energy (OPAE), Citizens Utility Board of Ohio (CUB Ohio), Interstate Gas Supply, LLC (IGS), Retail Energy Supply Association (RESA), NRG/Direct Energy Services, LLC and Direct Energy Business, LLC, Ohio Environmental Council (OEC), Ohio Cable Telecommunications Association (OCTA) and FirstEnergy’s Ohio utilities.

Focused on the Future

Between 2025 and 2029, FirstEnergy plans to invest $14 billion in Ohio’s transmission and distribution infrastructure, workforce and facilities – critical improvements that enhance reliability, support economic growth and prepare for future energy needs. The company looks forward to working constructively with the PUCO and other stakeholders to meet the needs of customers and communities across Ohio.

FirstEnergy (NYSE: FE) is dedicated to integrity, safety, reliability and operational excellence. Its electric distribution companies form one of the nation’s largest investor-owned electric systems, serving more than six million customers in Ohio, Pennsylvania, New Jersey, West Virginia, Maryland and New York. The company’s transmission subsidiaries operate approximately 24,000 miles of transmission lines that connect the Midwest and Mid-Atlantic regions. Follow FirstEnergy on X @FirstEnergyCorp or online at firstenergycorp.com.

Forward-Looking Statements: This Letter includes forward-looking statements based on information currently available to management and unless the context requires otherwise, references to “we,” “us,” “our” and “FirstEnergy” refers to FirstEnergy Corp. and its subsidiaries. Such statements are subject to certain risks and uncertainties and readers are cautioned not to place undue reliance on these forward-looking statements. These statements include declarations regarding management’s intents, beliefs and current expectations. These statements typically contain, but are not limited to, the terms “anticipate,” “potential,” “expect,” “forecast,” “target,” “will,” “intend,” “believe,” “project,” “estimate,” “plan” and similar words. Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, which may include the following: the potential liabilities, increased costs and unanticipated developments resulting from government investigations and agreements, including those associated with compliance with or failure to comply with the Deferred Prosecution Agreement entered into July 21, 2021 and settlements with the U.S. Attorney’s Office for the Southern District of Ohio and the Securities and Exchange Commission (“SEC”); the risks and uncertainties associated with government investigations and audits regarding Ohio House Bill 6, as passed by Ohio’s 133rd General Assembly (“HB 6”) and related matters, including potential adverse impacts on federal or state regulatory matters, including, but not limited to, matters relating to rates; the risks and uncertainties associated with litigation, arbitration, mediation and similar proceedings, particularly regarding HB 6 related matters; changes in national and regional economic conditions, including recession, volatile interest rates, inflationary pressure, supply chain disruptions, higher fuel costs, workforce impacts, affecting us and/or our customers and those vendors with which we do business; variations in weather, such as mild seasonal weather variations and severe weather conditions (including events caused, or exacerbated, by climate change, such as wildfires, hurricanes, flooding, droughts, high wind events and extreme heat events) and other natural disasters, which may result in increased storm restoration expenses or material liability and negatively affect future operating results; the potential liabilities and increased costs arising from regulatory actions or outcomes in response to severe weather conditions and other natural disasters; legislative and regulatory developments, and executive orders, including, but not limited to, matters related to rates, energy regulatory policies, compliance and enforcement activity, cyber security, climate change, and equity and inclusion; the ability to access the public securities and other capital and credit markets in accordance with our financial plans, the cost of such capital and overall condition of the capital and credit markets affecting us, including the increasing number of financial institutions evaluating the impact of climate change on their investment decisions, and the loss of FirstEnergy Corp.’s status as a well-known seasoned issuer; the risks associated with physical attacks, such as acts of war, terrorism, sabotage or other acts of violence, and cyber-attacks and other disruptions to our, or our vendors’, information technology system, which may compromise our operations, and data security breaches of sensitive data, intellectual property and proprietary or personally identifiable information; the ability to accomplish or realize anticipated benefits through establishing a culture of continuous improvement and our other strategic and financial goals, including, but not limited to, executing Energize365, our transmission and distribution investment plan, executing on our rate filing strategy, controlling costs, improving credit metrics, maintaining investment grade ratings, strengthening our balance sheet and growing earnings; changing market conditions affecting the measurement of certain liabilities and the value of assets held in our pension trusts may negatively impact our forecasted growth rate, results of operations and may also cause it to make contributions to its pension sooner or in amounts that are larger than currently anticipated; changes in assumptions regarding factors such as economic conditions within our territories, the reliability of our transmission and distribution system, our generation resource planning in West Virginia, or the availability of capital or other resources supporting identified transmission and distribution investment opportunities; human capital management challenges, including among other things, attracting and retaining appropriately trained and qualified employees and labor disruptions by our unionized workforce; mitigating exposure for remedial activities associated with retired and formerly owned electric generation assets, including those sites impacted by the legacy coal combustion residual rules that were finalized during 2024, and the Environmental Protection Agency’s reconsideration of such rule; changes to environmental laws and regulations, including, but not limited to, federal and state rules related to climate change, and potential changes to such laws and regulations as a result of the U.S. presidential administration; changes in customers’ demand for power, including, but not limited to, economic conditions, the impact of climate change, and emerging technology including artificial intelligence, particularly with respect to electrification, energy storage and distributed sources of generation; future actions taken by credit rating agencies that could negatively affect either our access to or terms of financing or our financial condition and liquidity; the potential of noncompliance with debt covenants in our credit facilities; the ability to comply with applicable reliability standards and energy efficiency and peak demand reduction mandates; changes to significant accounting policies; any changes in tax laws or regulations, including, but not limited to, the Inflation Reduction Act of 2022, the One Big Beautiful Bill Act of 2025, as signed into law on July 4, 2025, or adverse tax audit results or rulings and potential changes to such laws and regulations; the ability to meet our publicly-disclosed goals relating to climate-related matters, opportunities, improvements, and efficiencies, including FirstEnergy’s Greenhouse gas reduction goals’ and the risks and other factors discussed from time to time in FirstEnergy Corp.’s SEC filings. Dividends declared from time to time on FirstEnergy Corp.’s common stock during any period may in the aggregate vary from prior periods due to circumstances considered by the FirstEnergy Corp. Board at the time of the actual declarations. A security rating is not a recommendation to buy or hold securities and is subject to revision or withdrawal at any time by the assigning rating agency. Each rating should be evaluated independently of any other rating. These forward-looking statements are also qualified by, and should be read together with, the risk factors included in FirstEnergy Corp.’s Form 10-K, Form 10-Q and in other filings with the SEC. The foregoing review of factors also should not be construed as exhaustive. New factors emerge from time to time, and it is not possible for management to predict all such factors, nor assess the impact of any such factor on FirstEnergy Corp.’s business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statements. FirstEnergy Corp. expressly disclaims any obligation to update or revise, except as required by law, any forward-looking statements contained herein or in the information incorporated by reference as a result of new information, future events or otherwise.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/settlement-reached-in-multiple-puco-firstenergy-proceedings-302647220.html

SOURCE FirstEnergy Corp.

AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

PR Newswire

Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing

THOUSAND OAKS, Calif., Dec. 19, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced it is taking action again with the U.S. government to lower medicine costs for American patients, while reinforcing Amgen’s long-standing commitment to innovation. The action satisfies the components outlined in President Trump’s July 31 letter, including the Administration’s Most Favored Nation pricing requests. Additional details remain confidential.

“The U.S. leads the world in biopharmaceutical innovation, and we look forward to continued engagement with the U.S. government to see that this innovation is appropriately supported globally,” said Robert A. Bradway, chairman and chief executive officer at Amgen.

Amgen will expand its direct-to-patient program, AmgenNow™, to include Aimovig® (erenumab-aooe) and Amjevita® (adalimumab-atto). Both will be available at a discounted monthly price of $299, nearly 60% and 80% lower than their current U.S. list prices, respectively. In October 2025, the company launched AmgenNow and made Repatha® (evolocumab) available to American patients at a monthly price of $239, nearly 60% below its current U.S. list price. The program is open to all eligible patients, including those who are uninsured, enrolled in high-deductible health plans or prefer to pay with cash or out of pocket. All three medicines will also be offered through TrumpRx.gov.

Since 2018, Amgen has invested more than $40 billion in manufacturing and research and development, building on its leadership in innovation and state-of-the-art operations in the U.S. These investments were facilitated by the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. The enactment of pro-growth tax policies in the TCJA, reinforced by the One Big Beautiful Bill Act of 2025, further enabled Amgen to invest domestically in science and manufacturing.

This year, Amgen announced an additional $2.5 billion in U.S. manufacturing capital investments, including expansions of $900 million in Ohio and $1 billion in North Carolina. In recognition of these continued investments, Amgen will receive relief from industry-specific tariffs for the next three years.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads

Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon’s business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-takes-action-with-the-us-government-to-lower-the-cost-of-medicines-for-american-patients-302647210.html

SOURCE Amgen

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect American biopharma leadership

Company reinforces commitment to U.S. manufacturing and American jobs

FOSTER CITY, Calif.–(BUSINESS WIRE)–
Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based innovation, affordability, and global health leadership.

“This agreement reflects a foundational commitment to both affordability and future innovation, a commitment that we have long seen as essential to shaping the future of healthcare,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “The progress toward expanding access and increasing investment in U.S. innovation will meaningfully contribute to America’s health and economic priorities. Gilead Sciences will continue to work with the Administration in service of these priorities for the benefit of generations to come.”

As part of the three-year agreement, Gilead addresses all requests by President Trump to implement a new pricing strategy that prioritizes American patients, ensuring the U.S. no longer bears a disproportionate share of global healthcare costs. This includes:

  • Discounts on certain existing medicines within the U.S. Medicaid program, similar to what is paid in comparably developed nations, including select medications to treat HIV, Hepatitis C, Hepatitis B and COVID-19.
  • Pricing future medicines at parity with other key developed nations.
  • Launching a Direct-to-Patient Program where individuals with a prescription can obtain Gilead’s Hepatitis C treatment and cure, Epclusa®, at a discounted cash price. Gilead will make Epclusa available via TrumpRx.gov where American patients can be connected directly with Gilead’s Direct-to-Patient Program.
  • An agreement with the U.S. Department of Commerce to be exempt from Section 232 pharmaceutical tariffs for three years, provided Gilead further invests in manufacturing in the United States.

Based on these terms, the company expects the financial impact to be manageable in 2026 and beyond. Additional terms of the agreement with the U.S. government remain confidential.

This agreement reinforces America’s leadership in global health and biomedical innovation and builds upon Gilead’s recently announced landmark partnership with the U.S. Department of State to provide its breakthrough HIV prevention medicine, lenacapavir, at no profit to up to two million individuals in the most severely affected countries around the world over the next three years.

Gilead also recently announced it will invest $32 billion in U.S.-based manufacturing, R&D, and infrastructure over the next five years. This investment is projected to generate $43 billion in national economic value and create more than 3,000 direct and indirect jobs.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the impact of the agreement with the U.S. government and the Direct-to-Patient Program on Gilead’s business, operations and financial condition and results; risks related to the ability to realize the anticipated benefits of the agreement with the U.S. government and the Direct-to-Patient Program, including that patient access and other expected benefits will not be realized or will not be realized within the expected time periods; the uncertainties inherent in research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Gilead’s business and prospects, manufacturing expansion and capabilities, adverse developments in Gilead’s markets or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; and competitive developments; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

Epclusa® is a trademark of Gilead Sciences, Inc. or its related companies and the full prescribing information is available at https://www.gilead.com/medicines.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

Ashleigh Koss, Media

[email protected]

Jacquie Ross, Investors

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: COVID-19 Infectious Diseases Hospitals Public Policy/Government Healthcare Reform Biotechnology White House/Federal Government AIDS Pharmaceutical Health

MEDIA:

Logo
Logo

Northpointe Bancshares, Inc. Announces Date of Fourth Quarter 2025 Earnings Release and Conference Call

Northpointe Bancshares, Inc. Announces Date of Fourth Quarter 2025 Earnings Release and Conference Call

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–
Northpointe Bancshares, Inc. (NYSE: NPB), the holding company of Northpointe Bank, announced today that it will release its fourth quarter 2025 financial results on Tuesday, January 20, 2026, after market close. The earnings release will be available in the “Investor Relations” section of the Company’s website, ir.northpointe.com.

The Company will host a conference call for investors and analysts at 10:00 a.m. E.T. on January 21, 2026. During the call, management will discuss the fourth quarter 2025 financial results and provide an update on recent activities. There will be a live question-and-answer session following the presentation. It is recommended you join 10 minutes prior to the start time. Participants may access the live conference call by dialing 1-877-413-2414 and requesting “Northpointe Bancshares, Inc. Conference Call”. The conference call will also be webcast live at ir.northpointe.com. An audio archive will be available on the website following the call.

About Northpointe Bancshares, Inc.:

Headquartered in Grand Rapids, Michigan, Northpointe Bancshares, Inc. is the holding company of Northpointe Bank, a client-focused company that provides home loans and retail banking products to communities across the nation. Our mission is to be the best bank in America by bringing value and innovation to the people we serve. To learn more visit www.northpointe.com.

Kevin Comps, President

616-974-8491 | [email protected]

Brad Howes, CFO

616-726-2585 | [email protected]

KEYWORDS: Michigan United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Georgia PSC approves plan to deliver savings for electric customers, meet energy demands of a growing state

PR Newswire

Plan will deliver estimated savings of approximately $102 per year for the typical residential customer;
Growth continues to create thousands of new jobs and billions of dollars of positive economic impact
expected across Georgia

ATLANTA, Dec. 19, 2025 /PRNewswire/ — Georgia Power announced today that the Georgia Public Service Commission (PSC) has approved a plan which will allow the company to proceed with procuring approximately 9,900 megawatts (MW) of diverse, cost-effective generation resources to serve the energy needs of a growing state. The plan follows a stipulated agreement the company recently reached with the Public Interest Advocacy (PIA) Staff, where Georgia Power agreed that it will file its next base rate case in 2028 in a manner that will ensure incremental revenue from large-load customers will provide benefits of at least $556 million per year, equivalent to $8.50 per month (or approximately $102 per year) for the typical residential customer using 1,000 kilowatt-hours per month. These significant savings for Georgia Power customers reinforce the company’s commitment to delivering affordable energy for customers in the face of projected extraordinary growth, and follows the current freeze on the company’s base rates announced earlier this year.

Kim Greene, chairman, president and CEO of Georgia Power, highlighted the benefits of the agreement when it was reached with PIA Staff, saying, “We know every dollar counts. This plan means more money stays in your pocket while we power Georgia’s future. Unlike any other market in the country, we’re doing things differently here in Georgia to capture and serve this projected unprecedented growth. Large energy users are paying more so families and small businesses can pay less, and that’s a great result for Georgians.”

The plan approved today follows months of review and discussion of Georgia Power’s original filing in July, which requested the certification of more than 3,600 MW of new combined cycle natural gas generation; more than 3,000 MW of new battery energy storage systems (BESS); 350 MW of BESS plus solar; and more than 2,800 MW of power purchase agreements. These resources will serve and benefit all Georgia Power customers as part of a diverse generation mix, and construction projects are expected to positively impact communities across the state.

Georgia continues to experience extraordinary growth, with record-breaking investment in the state of more than $26 billion and more than 23,000 new private sector jobs expected from economic development activities in the last fiscal year, according to the Georgia Department of Economic Development. Georgia Power continues to work with the Georgia PSC to meet the projected demand for electricity, as growth drives new jobs and tax revenue for cities and counties across the state.

“Growth is good for Georgia and for communities of all sizes. The decision by the Georgia PSC today will help keep our state competitive by demonstrating that we are ready to meet the energy demands of new businesses for years to come,” added Greene. “We appreciate the work of the PSC, and all those who participated in this important process.”


Large-Load Growth Continues

Georgia Power will continue to file quarterly large-load reports with the Georgia PSC providing regular updates on forecasted growth and electrical demand. The company’s latest report in November highlights that large-load growth continues to materialize with thousands of megawatts of new electrical load projected in the coming years and construction underway or pending for nearly 30 large-load projects across the state. This growing pipeline of high-demand customers is a key factor enabling the company’s current three-year base rate freeze (excluding storm costs), helping to spread fixed costs across a broader customer base and protect residential and small business customers from paying more to serve large-load customers.

Following the Georgia PSC’s approval of updates to rules and regulations for the company in January, potential large-load customers must now meet more stringent criteria — including providing greater financial commitments and demonstrating infrastructure readiness — to remain in the company’s long-term development pipeline. These enhanced requirements help ensure that only the most credible and viable projects are included in Georgia Power’s risk-adjusted load forecast. The company has filed more than 3 gigawatts of new customer contracts with the Georgia PSC this year – agreements that were reached under the newly approved rules and regulations, which are designed to provide Georgia Power with the flexibility to sustainably serve large-load customers while safeguarding residential and small business customers from additional costs. Additional commitments are currently under evaluation by the company.

To learn more about how Georgia Power is keeping energy reliable and affordable for millions of Georgia homes and businesses, visit www.GeorgiaPower.com.


About Georgia Power 

Georgia Power is the largest electric subsidiary of Southern Company (NYSE: SO), America’s premier energy company. Value, Reliability, Customer Service and Stewardship are the cornerstones of the company’s promise to 2.8 million customers in all but four of Georgia’s 159 counties. Committed to delivering clean, safe, reliable and affordable energy, Georgia Power maintains a diverse, innovative generation mix that includes nuclear, coal and natural gas, as well as renewables such as solar, hydroelectric and wind. Georgia Power offers rates below the national average, focuses on delivering world-class service to its customers every day and the company is recognized by J.D. Power as an industry leader in customer satisfaction. For more information, visit www.GeorgiaPower.com and connect with the company on Facebook (Facebook.com/GeorgiaPower), X (X.com/GeorgiaPower) and Instagram (Instagram.com/ga_power).


Cautionary Note Regarding Forward-Looking Statements

Certain information contained in this release is forward-looking information based on current expectations and plans that involve risks and uncertainties. Forward-looking information includes, among other things, statements concerning projected demand growth and expected benefits from the approval of the stipulated agreement. Georgia Power cautions that there are certain factors that can cause actual results to differ materially from the forward-looking information that has been provided. The reader is cautioned not to put undue reliance on this forward-looking information, which is not a guarantee of future performance and is subject to a number of uncertainties and other factors, many of which are outside the control of Georgia Power; accordingly, there can be no assurance that such suggested results will be realized.  The following factors, in addition to those discussed in Georgia Power’s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, and subsequent securities filings, could cause actual results to differ materially from management expectations as suggested by such forward-looking information: state and federal rate regulations and the impact of pending and future rate cases and negotiations, including rate actions relating to return on equity, equity ratios, additional generating capacity and transmission facilities and fuel and other cost recovery mechanisms; the impact of recent and future federal and state regulatory changes, including tax, environmental and other laws and regulations to which Georgia Power is subject, as well as changes in application of existing laws, regulations and guidance; the extent and timing of costs and legal requirements related to coal combustion residuals; current and future litigation or regulatory investigations, proceedings or inquiries; the effects, extent and timing of the entry of additional competition in the markets in which Georgia Power operates, including from the development and deployment of alternative energy sources; variations in demand for electricity; available sources and costs of natural gas and other fuels and commodities; the ability to control costs and avoid cost and schedule overruns during the development, construction and operation of facilities or other projects; legal proceedings and regulatory approvals and actions related to past, ongoing and proposed construction projects; the ability to construct facilities in accordance with the requirements of permits and licenses, to satisfy any environmental performance standards and the requirements of tax credits and other incentives and to integrate facilities into the Southern Company system upon completion of construction; investment performance of the employee and retiree benefit plans and nuclear decommissioning trust funds; advances in technology, including the pace and extent of development of low- to no-carbon energy and battery energy storage technologies and negative carbon concepts; the ability to successfully operate Georgia Power’s generation, transmission and distribution facilities and the successful performance of necessary corporate functions; the inherent risks involved in operating nuclear generating facilities; the ability of counterparties of Georgia Power to make payments as and when due and to perform as required; the direct or indirect effect on Georgia Power’s business resulting from cyber intrusion or physical attack and the threat of cyber and physical attacks; global and U.S. economic conditions, including impacts from geopolitical conflicts, recession, inflation, changes in trade policies (including tariffs and other trade measures) of the United States and other countries, interest rate fluctuations and financial market conditions and the results of financing efforts; access to capital markets and other financing sources; changes in Georgia Power’s credit ratings; the ability of Georgia Power to obtain additional generating capacity (or sell excess generating capacity) at competitive prices; catastrophic events such as fires, earthquakes, explosions, floods, tornadoes, hurricanes and other storms, droughts, pandemic health events, political unrest, wars or other similar occurrences; the direct or indirect effects on Georgia Power’s business resulting from incidents affecting the U.S. electric grid or operation of generating resources; and the effect of accounting pronouncements issued periodically by standard-setting bodies. Georgia Power expressly disclaims any obligation to update any forward-looking information.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/georgia-psc-approves-plan-to-deliver-savings-for-electric-customers-meet-energy-demands-of-a-growing-state-302647182.html

SOURCE Georgia Power

Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Metaplanet Inc.

Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Metaplanet Inc.

NEW YORK–(BUSINESS WIRE)–
Deutsche Bank announced today its appointment as depositary bank for the American Depositary Receipt program of Metaplanet Inc.

Metaplanet Inc. (OTC: MPJPY) is a Japanese Bitcoin treasury company. The company leverages Bitcoin as its core treasury reserve asset, employing capital market strategies to accumulate BTC through equity and fixed income offerings while building complementary Bitcoin-focused business lines.*

In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. Deutsche Bank offers a very broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

* This information was provided by Metaplanet Inc. (December 2025).

Depositary Receipt Information

Depositary Receipt Contacts

Country

Japan

New Business

Development

William Ng

 

Custodian Bank

MUFG Bank Ltd of 1-3-2, Nihombashi Hongoku-cho, Chuo-ku, Tokyo 103-0021, Japan

Tel: +61 2 8258 1019

 

 

 

www.adr.db.com

Markets Distribution

 

 

[email protected]

London

Effective Date

December 19, 2025

 

Tel: +44 (0) 20 7547 6500

 

 

gtb.db.com

New York

Level I ADR

 

 

Tel: +1 212 250 9100

CUSIP

59141L 109

 

 

ISIN

US59141L1098

 

 

Symbol

MPJPY

 

 

Exchange

OTC

 

 

Current Ratio

1 ADS: 1 ordinary share

 

 

Eligibility

DTC

 

 

Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany’s leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the “Act”). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© December 2025 Deutsche Bank AG. All rights reserved.

For further information, please contact:

Deutsche Bank AG

Press & Media Relations

Dylan Riddle

Tel. +12122504982

Cell. +1(904)3866481

Email [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Finance Cryptocurrency Banking Professional Services Asset Management

MEDIA:

Logo
Logo